Atlas Trials

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Clinical trial NCT01928537 · COMPLETED

Trial details

NCT number
NCT01928537
Sponsor
Traws Pharma, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Myelodysplastic SyndromesRefractory Anemia With Excess BlastsChronic Myelomonocytic LeukemiaCytopenia
Start date
2013-08-01
Primary completion
2017-06-29
Enrollment
67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.